Nevada’s Vetoed Insulin Cost Transparency Bill Returns, as California Advances Several Pricing Measures Post author:Sam Post published:June 5, 2017 Post category:Drug Industry Daily Lawmakers in Nevada and California continue to target drugmakers in health care proposals. Source: Drug Industry Daily You Might Also Like FDA Draft Guidance Gives More Direction for Developing Antibacterial Drugs for Unmet Needs May 24, 2022 White House Will Seek Emergency Relief from Supreme Court on Mifepristone Decision April 13, 2023 U.S.-EU Partnership on GMP Inspections Adds Five Countries November 29, 2018
FDA Draft Guidance Gives More Direction for Developing Antibacterial Drugs for Unmet Needs May 24, 2022